BRIEF-Intelligent Bio Solutions Completes Clinical Cut-Off Study

Intelligent Bio Solutions Inc. +10.15%

Intelligent Bio Solutions Inc.

INBS

2.93

+10.15%

April 2 (Reuters) - Intelligent Bio Solutions Inc INBS.O:

  • INTELLIGENT BIO SOLUTIONS COMPLETES CLINICAL CUT-OFF STUDY, ADVANCES FDA 510(K) CLINICAL PROGRAM TARGETING MULTI-BILLION-DOLLAR U.S. DRUG SCREENING MARKET

  • INTELLIGENT BIO SOLUTIONS INC: NOW INITIATED SECOND PHASE OF ITS CLINICAL STUDY PROGRAM

  • INTELLIGENT BIO SOLUTIONS INC: EXPECTS TO COMPLETE METHOD COMPARISON AND USABILITY STUDY BY END OF JUNE 2026

  • INTELLIGENT BIO SOLUTIONS INC: COMPLETION OF INTERFERENCE STUDY IS ANTICIPATED BY END OF JULY 2026

Source text: ID:nGNX5gY6rl

Further company coverage: INBS.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.